Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

BACKGROUND: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detai...

Descripción completa

Detalles Bibliográficos
Autores principales: Farlow, Martin, Veloso, Felix, Moline, Margaret, Yardley, Jane, Brand-Schieber, Elimor, Bibbiani, Francesco, Zou, Heng, Hsu, Timothy, Satlin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126705/
https://www.ncbi.nlm.nih.gov/pubmed/21612646
http://dx.doi.org/10.1186/1471-2377-11-57

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126705/
https://www.ncbi.nlm.nih.gov/pubmed/21612646
http://dx.doi.org/10.1186/1471-2377-11-57

Ejemplares similares